MesenCure

Biologic

BBonusBio Group Ltd

MesenCure is one of 20 biologic programs targeting COVID-19. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

1 2

Activella

Eli Lilly

Preclinical

—3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

SARS-COV-2 VACCINE

Moderna

Preclinical

2 6

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 8

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 9

Conventional

PPopulation Health Research Institute

Preclinical

1 10

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Treatment

NCT05497401

Clinical

Trials by Indication[1]

Treatment1 trial

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

Not yet recruiting·BBonusBio Group Ltd·Phase 3·NCT05497401·300 enrolled

COVID-191 trial

Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19

Completed·BBonusBio Group Ltd·Phase 1/2·NCT04716998·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MesenCure. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MesenCure compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MesenCure. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BonusBio Group Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: BBonusBio Group Ltd

MesenCure

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Treatment1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News